Watch This Space: Glenmark-SaNOtize’s COVID-19 Nasal Spray Debuts In India
Executive Summary
Glenmark's partnered nitric oxide nasal spray for COVID-19 debuts in India at about $11, with the firm spotlighting the reduction in viral load with the product and potential to cut the chain of transmission. But more competition appears to be in the wings.
You may also be interested in...
Bharat Biotech Debuts World’s First Exclusively Intranasal COVID-19 Vaccine
With the world’s first exclusively intranasal COVID-19 vaccine against COVID-19 getting restricted use approval in India, Bharat Biotech/Washington University St. Louis offer an easy-to-use immunization option. But is it too little too late?
Canadian Firm Explores Potential Of Nasal Spray In COVID-19 Prevention
Dr Gilly Regev, CEO of the anti-infectives-focused firm, SaNOtize Research & Development Corp, remains confident of the effectiveness of the firm’s nitric oxide nasal spray against evolving variants of SARS-CoV-2 and expects to progress plans for a “prevention” trial in the US.
Glenmark Chief: Running A Facility In The US Has Been A Struggle
Glenmark readies scale up in the respiratory segment, with Ryaltris set for a US debut and a filing for a generic rival to Flovent anticipated. Running a facility in that market, though, is not an easy task, says the firm's leadership.